Immunotherapy Combined With Chemotherapy for Recurrent or Metastatic Disease
Nasopharyngeal carcinoma is relatively uncommon in Western countries but is more frequently diagnosed in China and parts of Southeast Asia. Because of this, Chinese cancer centers have extensive experience treating both newly diagnosed and recurrent disease.
For recurrent or metastatic nasopharyngeal carcinoma, an important first-line treatment strategy combines the PD-1 inhibitor toripalimab with gemcitabine and cisplatin chemotherapy.
The treatment generally begins with:
Toripalimab + gemcitabine + cisplatin
for a limited number of combination cycles.
After completion of chemotherapy, patients who continue to benefit may remain on toripalimab maintenance therapy.
The chemotherapy component rapidly reduces tumor burden by directly damaging cancer cells. Toripalimab blocks the PD-1 immune checkpoint, helping T cells remain active against the tumor and potentially producing more durable control.
The phase III JUPITER-02 study compared this combination with gemcitabine and cisplatin alone.
Median progression-free survival was 21.4 months with toripalimab plus chemotherapy compared with 8.2 months with chemotherapy alone. The objective response rate was approximately 78.8% versus 67.1%, and responses also lasted substantially longer in the toripalimab group.
Long-term follow-up also demonstrated an overall survival advantage. At three years, survival was approximately 64.5% in the toripalimab group versus 49.2% in the chemotherapy-only group.
Patients may be considered for this regimen if they have:
- Recurrent nasopharyngeal carcinoma that cannot be treated curatively with surgery or radiotherapy
- Newly diagnosed metastatic nasopharyngeal carcinoma
- Adequate renal and bone-marrow function for platinum chemotherapy
- Sufficient general physical condition for combined systemic treatment
Treatment monitoring typically includes CT or MRI imaging, blood counts, renal and liver tests, EBV DNA assessment when appropriate, and evaluation for immune-related adverse events.
For suitable patients, adding PD-1 immunotherapy to gemcitabine-cisplatin chemotherapy has substantially changed the first-line treatment strategy for recurrent or metastatic nasopharyngeal cancer.
